Faron Pharmaceuticals Oy Managers' transactions (6920M)
12 Mayo 2020 - 12:00PM
UK Regulatory
TIDMFARN
RNS Number : 6920M
Faron Pharmaceuticals Oy
12 May 2020
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Managers' transactions
Company announcement, 12 May 2020 at 8 PM (EEST)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), the clinical stage biopharmaceutical company,
announces today that Mr Toni Hänninen, Chief Financial Officer of
the Company, acquired 3,500 ordinary shares in Faron at a price of
EUR4.3255 per share on 12 May 2020. Following these purchases, Mr
Hänninen holds 50,297 ordinary shares in the Company.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ----------------------------------------------------------------------------------
a. Name Toni Hänninen
----------------------------------------------------
2 Reason for notification
---------------------------- ----------------------------------------------------
a. Position/Status Chief Financial Officer
---------------------------- ----------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---------------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
----------------------------
b. LEI 7437009H31TO1DC0EB42
---------------------------- ----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ----------------------------------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
---------------------------- ----------------------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
---------------------------- ----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
---------------------------- -----------
EUR4.3337 2,000
EUR4.3146 1,500
----------- -----------
Aggregated information
- Aggregated Volume 3,500
d. - Price EUR15,139.30
---------------------------- ----------------------------------------------------
e. Date of the transaction May 12, 2020
---------------------------- ----------------------------------------------------
f. Place of the transaction Nasdaq First North Growth Market
---------------------------- ----------------------------------------------------
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Panmure Gordon (UK) Limited, Nomad and Broker
Emma Earl, Freddy Crossley (Corporate Finance)
James Stearns (Corporate Broking)
Phone: +44 207 886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs. The Company currently has
a pipeline based on the receptors involved in regulation of immune
response in oncology and organ damage. Clevegen, its precision
immunotherapy, is a novel anti-Clever-1 antibody with the ability
to switch immune suppression to immune activation in various
conditions, with potential across oncology, infectious disease and
vaccine development. Currently in phase I/II clinical development
as a novel macrophage checkpoint immunotherapy for patients with
untreatable solid tumours, Clevegen has potential as a single-agent
therapy or in combination with other standard treatments including
immune checkpoint molecules. Traumakine, the Company's pipeline
candidate to prevent vascular leakage and organ failures, has
completed a phase III clinical trial in Acute Respiratory Distress
Syndrome (ARDS). Plans for its future development are being
finalised to avoid interfering steroid use together with
Traumakine. Faron is based in Turku, Finland. Further information
is available at www.faron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGPUPWAUPUGQP
(END) Dow Jones Newswires
May 12, 2020 13:00 ET (17:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
